DiaSorin Acquires COVID-19 Test Maker Luminex For $37 Per Share

Vandana Singh
1 min read
0
In this article:

  • Italian diagnostics firm DiaSorin SpA (OTCMKTS: DSRLF) has agreed to acquire Luminex Corporation (NASDAQ: LMNX) for $37 per share in an all-cash transaction, corresponding to a total equity value of approximately $1.8 billion.

  • The offer price represents around 23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February (the date before press rumors regarding a potential sale of the company).

  • Luminex makes COVID-19 laboratory tests along with a suite of other biological testing technologies.

  • In March, it applied to the FDA for emergency approval of a lab test that combines tests for COVID-19 and the flu.

  • The acquisition will broaden DiaSorin’s positioning in the molecular diagnostics space gaining access to Luminex’s molecular diagnostics multiplexing technology and a more significant foothold in the U.S. market.

  • Following the acquisition, the new entity will have a combined 2020 revenue of approximately €1.25 billion, adjusted EBITDA of roughly €472 million, and a favorable net financial position of about €335 million.

  • The transaction will be funded through a mix of cash and external financing. It’s expected to close in the third quarter.

  • DiaSorin also signed a $1.1 billion term loan due in 2026 and a $500 million bridge loan due within 12 months with a group of banks including BNP, Citi, Mediobanca, and UniCredit.

  • Price Action: LMNX shares gained 10.8% at $36.5, whiles DSRLF shares are up 0.49% at $165.81 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories